$228 Million is the total value of Prosight Management, LP's 38 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 76.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZBH | Buy | ZIMMER BIOMET HLDGS INC | $19,458,000 | +10.7% | 130,000 | +1.6% | 8.54% | -12.3% |
| QURE | Sell | UNIQURE NV | $17,019,000 | +31.4% | 237,500 | -27.8% | 7.47% | +4.0% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $14,904,000 | +99.6% | 328,129 | +101.1% | 6.54% | +58.0% |
| KURA | Buy | KURA ONCOLOGY INC | $14,245,000 | +5.7% | 1,036,000 | +16.6% | 6.26% | -16.3% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $14,198,000 | +33.9% | 161,195 | +21.3% | 6.23% | +6.0% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $12,859,000 | +155.9% | 62,900 | +0.5% | 5.65% | +102.6% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $10,756,000 | +70.7% | 388,600 | +12.3% | 4.72% | +35.1% |
| ACIU | Sell | AC IMMUNE SA | $10,589,000 | +71.3% | 1,242,843 | -0.4% | 4.65% | +35.6% |
| MGTX | Buy | MEIRAGTX HOLDINGS PLC | $10,367,000 | +92.2% | 517,844 | +53.2% | 4.55% | +52.1% |
| ARQL | Buy | ARQULE INC | $8,989,000 | +243.6% | 450,326 | +23.4% | 3.95% | +172.0% |
| CNC | Sell | CENTENE CORP DEL | $8,978,000 | +25.8% | 142,800 | -13.5% | 3.94% | -0.4% |
| ALDX | Buy | ALDEYRA THERAPEUTICS INC | $8,298,000 | +99.2% | 1,428,277 | +80.7% | 3.64% | +57.7% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $7,841,000 | +29.3% | 92,737 | +3.1% | 3.44% | +2.4% |
| URGN | Sell | UROGEN PHARMA LTD | $7,264,000 | -6.3% | 217,686 | -33.1% | 3.19% | -25.9% |
| New | ARENA PHARMACEUTICALS INCcall | $6,468,000 | – | 142,400 | +100.0% | 2.84% | – | |
| ALBO | Sell | ALBIREO PHARMA INC | $6,283,000 | +24.4% | 247,178 | -2.1% | 2.76% | -1.5% |
| NVST | New | ENVISTA HLDGS CORP | $4,891,000 | – | 165,000 | +100.0% | 2.15% | – |
| PSNL | Buy | PERSONALIS INC | $4,433,000 | +162.2% | 406,673 | +253.0% | 1.95% | +107.5% |
| ANAB | New | ANAPTYSBIO INC | $3,816,000 | – | 234,823 | +100.0% | 1.68% | – |
| IMVT | New | IMMUNOVANT INC | $3,566,000 | – | 224,702 | +100.0% | 1.57% | – |
| ORGO | New | ORGANOGENESIS HLDGS INC | $2,972,000 | – | 617,836 | +100.0% | 1.30% | – |
| EOLS | New | EVOLUS INC | $2,884,000 | – | 236,939 | +100.0% | 1.27% | – |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $2,669,000 | -2.6% | 391,894 | -29.8% | 1.17% | -22.9% |
| SBBP | Sell | STRONGBRIDGE BIOPHARMA PLC | $2,630,000 | -56.2% | 1,258,224 | -50.0% | 1.16% | -65.4% |
| RCM | Sell | R1 RCM INC | $2,596,000 | -28.9% | 200,000 | -51.1% | 1.14% | -43.7% |
| EVH | New | EVOLENT HEALTH INCcl a | $2,528,000 | – | 279,390 | +100.0% | 1.11% | – |
| CI | Buy | CIGNA CORP NEW | $2,309,000 | +38.3% | 11,293 | +2.7% | 1.01% | +9.5% |
| MTEM | Sell | MOLECULAR TEMPLATES INC | $2,250,000 | +53.1% | 160,883 | -27.9% | 0.99% | +21.2% |
| CUE | New | CUE BIOPHARMA INC | $2,185,000 | – | 137,628 | +100.0% | 0.96% | – |
| New | ALLAKOS INCput | $1,974,000 | – | 20,700 | +100.0% | 0.87% | – | |
| PRTK | New | PARATEK PHARMACEUTICALS INC | $1,814,000 | – | 450,000 | +100.0% | 0.80% | – |
| TNET | New | TRINET GROUP INC | $1,591,000 | – | 28,104 | +100.0% | 0.70% | – |
| KZR | New | KEZAR LIFE SCIENCES INC | $1,283,000 | – | 320,000 | +100.0% | 0.56% | – |
| TLGT | Sell | TELIGENT INC NEW | $632,000 | -72.8% | 1,484,527 | -39.3% | 0.28% | -78.5% |
| New | AXSOME THERAPEUTICS INCput | $620,000 | – | 6,000 | +100.0% | 0.27% | – | |
| MIST | New | MILESTONE PHARMACEUTICALS IN | $616,000 | – | 38,481 | +100.0% | 0.27% | – |
| BMY | Sell | BRISTOL MYERS SQUIBB CO | $520,000 | -96.6% | 8,100 | -97.3% | 0.23% | -97.3% |
| APEN | New | APOLLO ENDOSURGERY INC | $454,000 | – | 159,336 | +100.0% | 0.20% | – |
| MLND | Exit | MILLENDO THERAPEUTICS INC | $0 | – | -52,051 | -100.0% | -0.20% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -2,366,707 | -100.0% | -0.51% | – |
| UROV | Exit | UROVANT SCIENCES LTD | $0 | – | -102,657 | -100.0% | -0.54% | – |
| Exit | REATA PHARMACEUTICALS INCcall | $0 | – | -12,300 | -100.0% | -0.55% | – | |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -587,626 | -100.0% | -1.28% | – |
| ADMA | Exit | ADMA BIOLOGICS INC | $0 | – | -548,409 | -100.0% | -1.35% | – |
| GH | Exit | GUARDANT HEALTH INC | $0 | – | -41,700 | -100.0% | -1.48% | – |
| FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -153,303 | -100.0% | -1.54% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -39,000 | -100.0% | -1.64% | – |
| HUM | Exit | HUMANA INC | $0 | – | -12,000 | -100.0% | -1.70% | – |
| HNGR | Exit | HANGER INC | $0 | – | -395,000 | -100.0% | -4.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-09-01 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.